Stockreport

Entrada Therapeutics Announces $100 Million Registered Direct Offering

Entrada Therapeutics, Inc.  (TRDA) 
PDF BOSTON, June 24, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of pati [Read more]